MAPS 2025

MAPS 2025 Decoded: The Medical Affairs Playbook for Successful Drug Launches

At the MAPS Americas 2025 conference in New Orleans, one of the pivotal discussions centered around preparing for drug launches in the current pharmaceutical landscape. While many important topics were covered, a critical element that was notably missing from the discussion was the need for a strategic north star—a guiding philosophy that ensures all tactical…...
Read More

Top Stories

DIA MASC 2025

Medical Affairs 2.0: GenAI as the Catalyst for

Digital and AI were hot topics underpinning many of the...
Biopharma 2025 Trends

Biopharma Trends 2025: 3 Things to Know Right Now

The global business climate is ever-evolving, and 2025 looks...

The Paradigm Shift from Traditional Scientific

In the rapidly evolving biopharma landscape, the approach to...

Bringing New Devices to Market under the EU MDR

With the MDR coming into effect, the manufacturers should plan and construct their strategy to...
Medical Affairs - 2025

Vision 2025: Decoding the Medical Affairs Landscape

Medical Affairs is a critical strategic pillars of pharma. Read how Medical Affairs will evolve...
Using digital enhancements to maximize engagement

Using Digital Enhancements to Maximize Engagement: How Are Pharma and Publishers Embracing Digital?

Best practices to implement digital enhancements and measure effectiveness...
Pros and cons of preprints for pharma

Preprints and Pharma: What Works and What Doesn’t

Pharma is cautious of preprints. But should this change? Let’s weigh the pros & cons...
Simplifying the omnichannel approach to publication planning

Simplifying the Omnichannel Publication Planning Approach

While the pharma and publication industries use multiple channels like emails, social media, conferences, and...
Image for the graphical abstracts blog by Cactus Life Sciences

Reel Your Audience in with a Visual Abstract

Graphical abstracts allow room for science communication to be reimagined in a range of creative...

Learn more ABOUT our company.